Open AccessAngiotensin II blockers improve cardiac coronary flow under hemodynamic pressure overload
Author(s) -
WeiTing Chang,
Sudeshna Fisch,
Seema Dangwal,
Michael Chen,
Susan Cheng,
ZhihCherng Chen,
Ronglih Liao
Publication year - 2021
Publication title -
hypertension research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.022
H-Index - 89
eISSN - 1348-4214
pISSN - 0916-9636
DOI - 10.1038/s41440-021-00617-1
Subject(s) - medicine , cardiology , pressure overload , afterload , angiotensin ii , heart failure , hemodynamics , cardiac fibrosis , hypertensive heart disease , cardiac function curve , blood pressure , cardiac hypertrophy
Coronary flow velocity (CFV) is reduced in pathologic cardiac hypertrophy. This functional reduction is linked to adverse cardiac remodeling, hypertension and fibrosis, and angiotensin II (AngII) is a key molecular player. Angiotensin receptor blockers (ARBs) are known to attenuate adverse cardiac remodeling and fibrosis following increased afterload, while the mechanism by which these drugs offer clinical benefits and regulate hemodynamics remains unknown. To establish a direct connection between coronary flow changes and angiotensin-induced hypertension, we used a Doppler echocardiographic method in two distinct disease models. First, we performed serial echocardiography to visualize coronary flow and assess heart function in patients newly diagnosed with hypertension and currently on ARBs or calcium channel blockers (CCBs). CFV improved significantly in the hypertensive patients after 12 weeks of ARB treatment but not in those treated with CCBs. Second, using murine models of pressure overload, including Ang II infusion and aortic banding, we mimicked the clinical conditions of Ang II- and mechanical stress-induced hypertension, respectively. Both Ang II infusion and aortic banding increased the end-systolic pressure-volume relationship and cardiac fibrosis, but interestingly, only Ang II infusion resulted in a significant reduction in CFV and corresponding activation of pressure-sensitive proteins, including connective tissue growth factor, hypoxia-inducible factor 1α and signal transducer and activator of transcription 3. These data support the existence of a molecular and functional link between AngII-induced hemodynamic remodeling and alterations in coronary vasculature, which, in part, can explain the clinical benefit of ARB treatment in hypertensive patients.